Medindia

X

Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009

Monday, October 26, 2009 General News J E 4
Advertisement

SAN DIEGO, Oct. 26 -- Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference.  Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.  

The Company's flu program has identified a compound, IkT-041, comparable in activity to viral neuraminidase inhibitors (e.g. Tamiflu, Relenza), but one that is far less likely to stimulate resistance.  IkT-041 has excellent human dosing metrics (up to 3000 mg/day), outstanding safety history in humans and an oral bioavailability > 70%.

The Company's orphan drug program is focused on satisfying an unmet medical need for the treatment of polyomavirus infections.  The human polyomaviruses, JC and BK, are responsible for fatal disorders of the brain and kidney, to include progressive multifocal leukoencephalopathy (PML), an AIDS-defining disease that also afflicts patients on autoimmune disorder treatments for MS, lupus and arthritis.  IkT-001 has a mechanism of action that can suppress polyomavirus reactivation in viral reservoirs, even in patients who are immune compromised.  In some cases, a therapeutic vaccine effect can be realized with this product.

The Company is on track to file 3 Initial New Drug applications in 2010 or early 2011 and enter late stage clinical trials shortly thereafter.  First product launch is slated for 2013, addressing a total market of greater than 100 million patients with annual revenue potential of at least $2.3 billion.

SOURCE Inhibikase Therapeutics

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Garth Fisher, M.D.(R), F.A.C.S., Announces Adoptio...
S
AMD LASERS Announces Partnerships With Three Indus...